Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (383)	1/16/2007 2:35:05 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 588

Tuck: I don't want you thinking I didnt take your pointer to that animal data seriously. Between that and the one leukopenia case, I raised the possibility in the recently released January issue of NI that Acadia might eventually have to drop ACP-104: because it may not be viable as a monotherapy, and there may be better (nicotinics or AMPA modulators to name two possibilities) adjunctive therapies coming along. When I saw Acadia at JPM, they did not concur with this hypothesis. Harry NeuroInvestment